RE:RE:RE:RE:RE:RE:RE:This is what is actually happeningThey don't have to report the name of the company they acquired it from. As a matter of fact, there might even be a non-disclosure agreement. Who cares who they acquired it from ? What even makes you think it's from a known public company ? Plenty of companies selling meds around the globe to buy from. Geez.
Lattice wrote: CNInvesting, Nah.... This is a pattern in CXR press releases. Just like how they left out the company name of who they acquired their 4 drugs from speaks VOLUMES. The coverup is always worse than the crime and it will be Thompson that will fry.
CNInvesting wrote: Lattice wrote: select1011 wrote: Greenhill runs good processes, but I wouldn't know what the client (MT) actually enlisted Greenhill to do and how.
CNInvesting wrote: We disagree on the Brexit select but I too find this theory interesting. However, if we elaborate a bit more, why would they set such a deadline and why would there be any ''kicking out'' ? You think this might have anything to do with Greenhill running this whole process ? Thoughts appreciate
It is important for investors to recognize what isn't said in CXR's press releases and to understand the game they are playing. Greenhill's name is absent from today's press release, I certainly would not assume that they are still engaged as Concordia's pimp. #Wasn'tBornYesterday
Thanks for vomitting back what Cohodes is saying on Twitter Lattice. However, the absence of their name on the last PR is irrelevant. They were hired to review this process with CXR and most likely still are as they generally work based off of contracts. If they are not, it's because they've done their job in finding potential suitors and now negociations are on. We still have no official confirmation from any party, so you're speculating at most.